EyePoint's Phase 2 PAVIA trial of Duravyu for non-proliferative diabetic retinopathy failed to meet primary endpoint, causing a 32% stock drop.
EyePoint Pharmaceuticals stock plummeted 32% on Monday after the company's Phase 2 PAVIA trial of Duravyu (vorolanib intravitreal insert) for non-proliferative diabetic retinopathy didn't meet its pre-specified primary endpoint. Despite showing a biologic effect and favorable safety profile, the trial results were deemed insufficient. The company plans to discuss the full 12-month data and future plans for Duravyu.
May 06, 2024
4 Articles